FDA Approves AVM0703 Clinical Trials in R/R Non-Hodgkins Lymphoma
Seattle, April 20, 2020 – AVM Biotechnology announces clinical trial approval for AVM0703, an exciting new drug to treat terminal no-option Non-Hodgkin’s Lymphoma, Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia.